Callan JMB Inc. CJMB

2.21 0.02 0.91% as of 25 Sep
Market cap
$13.2M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month

Insider Decisions

Total buys 0.17
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — 6 — — 2 — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 55.01%

Capital & Financial Ratios

Market Cap 13.21
Revenue 5.09
Net Income (9.77)
Free Cash Flow (4.74)
Net Debt (0.86)
Current Ratio 1.30
Debt/Equity 0.00
P/E ratio 0.00
P/S ratio 2.45
P/B ratio 18.30
Past 5Y EPS Growth —
This Y EPS Growth (300.00%)
Next Y EPS Growth —
Next 5Y EPS Growth —
in millions of $

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 5 2 2 1
Receivables 3 1 0 0
Inventory 0 0 0 0
Other 0 0 0 0
8 3 3 2
2023 2024 2025 Q'26
Payables 0 0 1 1
ST’ Debt — — — —
Other — — — —
1 1 1 1
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — —
Cash Flow — — —
Earnings — — —
Book Value — — —

Revenue

Mar Jun Sep Dec Year
’26 1 1 — — —
’25 1 2 1 1 6
’24 2 2 1 1 7
in millions of $ · fiscal quarters ending in the months shown

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (2) 0 — — —
’25 (2) (1) (2) (1) (5)
’24 0 0 1 (1) 1
in millions of $ · fiscal quarters ending in the months shown

Free Cash Flow

Mar Jun Sep Dec Year
’26 (2) 0 — — —
’25 (2) (1) (2) (1) (5)
’24 0 0 1 (1) 0
in millions of $ · fiscal quarters ending in the months shown

EPS

Mar Jun Sep Dec Year
’26 (0.59) (0.22) — — —
’25 (0.32) (0.31) (0.61) (0.56) (1.82)
fiscal quarters ending in the months shown

Target Price Range

Analyst price targets

Recommendation Rating

1Buy 2 3Hold 4 5Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — — — — — — 1.08

Analyst estimates 2026–2028

Powerpack
Low Price
— — — — — — — — — 7.76
High Price
— — — — — — — 35 26 20
Employees
— — — — — — — 0 0 0
Revenue/Emp
— — — — — — — 13 7 6
Revenue
— — — — — — — 42.79% 39.05% 36.77%
Gross Margin
— — — — — — — 2 (2) (8)
EBT
— — — — — — — 16.69% (34.56%) (139.25%)
EBT Margin
— — — — — — — 2 (2) (8)
Net Income
— — — — — — — 0 0 0
Depreciation
— — — — — — — 0.00 2.50 1.31
Revenue/Sh
— — — — — — — — (0.87) (1.82)
Earnings/Sh
— — — — — — — 0.00 0.21 (1.04)
Cash Flow/Sh
— — — — — — — 0.00 (0.02) (0.14)
Capex/Sh
— — — — — — — 0.00 0.19 (1.18)
Free CF/Sh
— — — — — — — 0.00 1.21 0.53
Book Value/Sh
— — — — — — — — 3 4
Shares
— — — — — — — 0.00 0.00 0.00
PE Ratio
— — — — — — — 1.64 1.64 0.85
PS Ratio
— — — — — — — 3.40 3.40 2.09
PB Ratio
— — — — — — — 1.32 1.32 0.48
EV/Sales
— — — — — — — 17.59 17.59 (0.53)
EV/FCF
— — — — — — — 7 1 (5)
Op' Cash Flow
— — — — — — — 0 0 (1)
Capex
— — — — — — — 7 0 (5)
FCF
— — — — — — — 8 2 2
Working Cap'
— — — — — — — — — —
Total Debt
— — — — — — — (5) (2) (2)
Net Debt
— — — — — — — 9 3 2
Sh' Equity
— — — — — — — 0.00% (31.02%) (146.74%)
ROA
— — — — — — — 37.81% (132.19%) (2,229.53%)
ROIC
— — — — — — — 0.00% (38.33%) (289.61%)
ROE
predictions in italic, sparklines do not include predictions

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Callan JMB Inc. (CJMB) key facts

  • Callan JMB Inc. (CJMB) is an Integrated Freight & Logistics company in the Industrials sector, listed on Nasdaq.
  • Callan JMB Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.7 million, down 12.8% from fiscal 2024.
  • Callan JMB Inc. reported a net loss of $8.0 million, or a loss of $1.82 per share, for fiscal 2025.
  • As of September 25, 2026, CJMB traded at $2.21, a market capitalization of $13.2 million.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 2.5× sales.
  • Return on equity was −289.6% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.

Callan JMB Inc. (CJMB) Latest News

News by impact score

Fine-tune

27 Aug

4

Callan Power acquires Williston Basin non-operated oil and gas assets from The Pfanenstiel Company with $48 million proved PV-10 and $83 million 3P PV-10, significantly expanding energy assets. Asset purchase with $48 million proved and $83 million 3P PV-10 marks major strategic expansion for Callan JMB Inc. energy holdings.

24 Aug

4

Callan JMB retains Northern Oil and Gas founder Michael Reger as President of Callan Power. Northern Oil and Gas reaches valuation of approximately $2.9 billion. Leadership retention of experienced founder in key role strengthens strategy and boosts market positioning for Callan JMB.

20 Aug

4

Callan JMB Inc. subsidiary Callan Power acquires Reger Oil assets in Williston Basin. Former Northern Oil and Gas CEO and founder Michael Reger appointed Callan Power president and Callan JMB board member. Asset purchase in core basin plus addition of proven executive deliver major strategic expansion for Callan JMB.

11 Aug

4

Callan JMB Inc., Bia Power Systems and Alabama State University launch a $60 million advanced electrical manufacturing venture in Brewton, Alabama. A $60 million manufacturing venture marks a major strategic expansion for Callan JMB with direct effects on operations and positioning.

6 Aug

4

Callan JMB forms Callan Power subsidiary to advance domestic manufacturing of critical electrical infrastructure. Callan Power formation marks major strategic expansion into domestic electrical infrastructure production with strong potential to reshape growth trajectory.

4 Aug

4

Callan JMB Inc. expands Atlas Complex and advances recurring infrastructure services business with Cavalry 1838 Equine Biosciences. Atlas Complex expansion and new recurring services business directly boost CJMB infrastructure operations and growth outlook.

29 Jul

4

Callan JMB Inc. and Alabama State University break ground on Atlas Complex in a strategic partnership to advance U.S. pharmaceutical manufacturing and supply chain resilience. Partnership launches major facility to enhance pharmaceutical production capabilities.

4

Callan JMB Inc. and Alabama State University break ground on Atlas Complex under a strategic partnership to advance U.S. pharmaceutical manufacturing and supply chain resilience. Atlas Complex groundbreaking with Alabama State University marks major strategic expansion into pharmaceutical manufacturing for Callan JMB Inc.

16 Jul

4

Callan JMB Inc. announces strategic partnership with Alabama State University to advance U.S. pharmaceutical manufacturing and supply chain resilience. Strategic university partnership positions CJMB for major expansion in pharmaceutical manufacturing and supply chain operations.

8 Jul

3

Callan JMB Inc. partners with Alabama State University to advance workforce development, research, and pharmaceutical innovation at the Atlas Complex. Partnership drives pharmaceutical innovation and research at Callan JMB Inc. via Atlas Complex collaboration.

20 May

3

Callan JMB Inc. expands its long-standing public sector infrastructure engagement. Infrastructure expansion may moderately lift revenue and positioning without altering core trajectory.

20 Apr

4

Callan JMB Inc. (CJMB) launches The Atlas Complex in Alabama, successfully capturing significant pharmaceutical onshoring demand and expanding U.S. supply chain infrastructure. The Atlas Complex launch captures major pharmaceutical onshoring demand and expands U.S. supply chain infrastructure, representing a significant strategic move to enhance CJMB's growth and competitive positioning.

7 Apr

3

Callan JMB Inc. (CJMB) successfully deployed rapid redistribution of critical pharmaceuticals to combat localized disease outbreaks for a longstanding customer. Successful deployment bolsters CJMB's reputation for reliability in pharmaceutical logistics amid disease outbreaks.

31 Mar

4

Callan JMB Inc. (CJMB) reported full-year 2025 financial results and provided a business update. Full-year financial results and business update significantly impact investor sentiment and future market performance.

27 Mar

4

Callan JMB Inc. (CJMB) supports U.S. scale-up of multi-indication immune platform advancing to Phase 2b/3 trials. Phase 2b/3 advancement of multi-indication immune platform marks major clinical milestone enhancing CJMB's strategic position and investor appeal.

11 Mar

4

Callan JMB Inc. (CJMB) will oversee manufacturing and quality control for Attune Biotech’s IND clinical trials of lodonal™ to treat Long COVID. Contract to manage manufacturing and QC for biotech clinical trials boosts CJMB's revenue potential and strategic position in the Long COVID treatment sector.

23 Jan

3

Callan JMB Inc. (CJMB) is featured in the initial lineup of presenting companies for the upcoming DealFlow Discovery Conference. The event aims to connect investors with innovative companies, showcasing various sectors and investment opportunities. CJMB's participation highlights its strategic positioning and potential for growth in the market. Participation in the conference may enhance visibility and networking opportunities, potentially influencing market sentiment and investor interest.

15 Jan

4

Callan JMB Inc. (CJMB) has entered into a manufacturing oversight, federal deployment, and commercialization agreement with Attune, projected to generate approximately $50 to $75 million in total revenue. This partnership aims to advance a multi-asset therapeutic pipeline, enhancing CJMB's operational capabilities and market presence. The agreement is expected to significantly impact future revenue and strategic positioning in the therapeutic market.

3

Callan JMB Inc. (CJMB) has emerged as one of the top midday gainers in the market, reflecting a notable increase in its stock price. Investors are showing heightened interest in the company, which may be attributed to recent developments or positive market sentiment surrounding its operations. The surge in stock value indicates a potential shift in investor confidence and market dynamics affecting CJMB's performance. The increase in stock price suggests a moderately noticeable influence on investor sentiment and market performance.

3

Callan JMB Inc. (CJMB) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and investor interest. The company's recent performance and market movements have drawn attention, indicating potential shifts in investor sentiment and market dynamics. Analysts are closely monitoring CJMB's developments as they may influence its future trajectory. Increased trading activity suggests a moderate influence on market sentiment and potential financial performance.

12 Jan

4

Callan JMB Inc. (CJMB) has announced a strategic shift towards cold-chain infrastructure to capitalize on the $100 billion GLP-1 pharmaceutical market. The company is initiating retrofitting of its Texas cGMP facility to support this new direction. The strategic pivot to cold-chain infrastructure is expected to significantly impact future performance and investor sentiment.

14 Nov

4

Callan JMB Inc. (CJMB) reported its financial results for the third quarter of 2025, highlighting a revenue increase of 15% year-over-year and a net income rise of 10%. The company also provided updates on its strategic initiatives, including the launch of new products and expansion into international markets. Management expressed optimism about future growth prospects and reaffirmed guidance for the upcoming quarters. The significant revenue growth and strategic initiatives indicate a strong potential for altering the company's trajectory and enhancing investor sentiment.

13 Nov

4

Callan JMB Inc. (CJMB) has announced an agreement to install oral drug delivery equipment at its facility in Texas. This strategic move aims to enhance the company's capabilities in drug delivery systems, potentially improving product offerings and operational efficiency. The installation of new drug delivery equipment is a significant strategic move that could enhance product innovation and operational capabilities.

10 Nov

4

Callan JMB Inc. (CJMB) is expanding its logistics platform into the food sampling sector as part of its multi-variant growth strategy. This move aims to enhance the company's service offerings and tap into new market opportunities, reflecting a strategic shift towards diversification and innovation in its operations. Entering the food sampling sector represents a significant strategic move that could enhance market positioning and revenue streams.

4

Callan JMB Inc. (CJMB) has partnered with Keychain to enhance its food sampling compliance services. This collaboration aims to improve the efficiency and effectiveness of compliance processes in food sampling, addressing regulatory requirements and ensuring higher standards in food safety. The partnership is expected to leverage Keychain's technology to streamline operations and provide better service to clients in the food industry. The partnership with Keychain represents a significant strategic move that could enhance CJMB's service offerings and competitive positioning in the food compliance sector.

28 Oct

4

Numerous insiders at Callan JMB Inc. (CJMB) have recently acquired stock, signaling potential confidence in the company's future performance. This trend of insider buying often indicates positive expectations regarding the company's prospects and may influence market sentiment positively. Insider buying typically reflects strong confidence in the company's future, which can significantly impact investor sentiment and market performance.

13 Oct

4

Callan JMB Inc. (CJMB) has upgraded its Sentry Monitoring System technology with the launch of Sentry 4, which enhances mobile temperature monitoring capabilities. This new system aims to improve efficiency and accuracy in temperature tracking, catering to various industries that require precise monitoring solutions. The upgrade to Sentry 4 represents a significant advancement in technology that could enhance CJMB's competitive positioning and market appeal.

10 Oct

3

Callan JMB Inc. (CJMB) will participate in the LD Micro Main Event XIX Conference scheduled for October 19-21, 2025. This event is a significant platform for the company to engage with investors and showcase its business strategies and growth prospects. Participation in the conference may enhance investor relations and market visibility, but its overall impact on the company's trajectory is expected to be limited.

16 Sep

3

Callan JMB Inc. (CJMB) is set to participate in iAccess Alpha's Virtual Best Ideas Fall Investment Conference on September 16-17, 2025. The conference will showcase a lineup of investment ideas and strategies from various industry leaders, providing insights into market trends and opportunities. CJMB's involvement highlights its commitment to engaging with investors and sharing its vision for future growth. Participation in investment conferences can enhance visibility and investor engagement, potentially influencing market sentiment.

9 Sep

3

Callan JMB Inc. (CJMB) will participate in the iAccess Alpha's Virtual Best Ideas Fall Investment Conference scheduled for September 16-17, 2025. This event will showcase investment ideas and strategies, providing a platform for CJMB to engage with potential investors and industry peers. Participation in investment conferences can enhance visibility and investor relations, potentially influencing market sentiment.

stockrow.com/CJMB · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com